This has been implicated in various cancers, but its specific role and prevalence in HS have not been well-documented. Therefore, ARID2 mutations do not appear to play a significant role in the RAS/RAF/MAPK and PI3K/AKT pathways in HS [12]. The gene discussed is ARID2; the disease is cancer.